

# **ANNUAL SYNAR REPORT**

**42 U.S.C. 300x-26**

**OMB № 0930-0222**

**FFY 2022**  
**State: Guam**

## **Table of Contents**

|                                                            |    |
|------------------------------------------------------------|----|
| Introduction.....                                          | i  |
| FFY 2022: Funding Agreements/Certifications .....          | 1  |
| Section I: FFY 2021 (Compliance Progress).....             | 2  |
| Section II: FFY 2022 (Intended Use) .....                  | 11 |
| Appendix A: Forms 1–5 .....                                | 13 |
| Appendixes B & C: Forms .....                              | 20 |
| Appendix B: Synar Survey Sampling Methodology .....        | 19 |
| Appendix C: Synar Survey Inspection Protocol Summary ..... | 21 |
| Appendix D: List Sampling Frame Coverage Study .....       | 25 |

**Public Burden Statement:** An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0930-0222. Public reporting burden for this collection of information is estimated to average 18 hours per respondent, per year, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to SAMHSA Reports Clearance Officer, 5600 Fishers Lane, Rockville, MD 20857.

## **INTRODUCTION**

The Annual Synar Report (ASR) format provides the means for states to comply with the reporting provisions of the Public Health Service Act (42 U.S.C. 300x-26) and the Tobacco Regulation for the Substance Abuse Prevention and Treatment Block Grant (SABG) (45 C.F.R. 96.130 (e)).

### **How the Synar report helps the Center for Substance Abuse Prevention**

In accordance with the tobacco regulations, states are required to provide detailed information on progress made in enforcing youth tobacco access laws (FFY 2021 Compliance Progress) and future plans to ensure compliance with the Synar requirements to reduce youth tobacco access rates (FFY 2022 Intended Use Plan). These data are required by 42 U.S.C. 300x-26 and will be used by the Secretary to evaluate state compliance with the statute. Part of the mission of the Center for Substance Abuse Prevention (CSAP) is to assist states<sup>1</sup> by supporting Synar activities and providing technical assistance helpful in determining the type of enforcement measures and control strategies that are most effective. This information is helpful to CSAP in improving technical assistance resources and expertise on enforcement efforts and tobacco control program support activities, including state Synar program support services, through an enhanced technical assistance program involving conferences and workshops, development of training materials and guidance documents, and onsite technical assistance consultation.

### **How the Synar report can help states**

The information gathered for the Synar report can help states describe and analyze substate needs for program enhancements. These data can also be used to report to the state legislature and other state and local organizations on progress made to date in enforcing youth tobacco access laws when aggregated statistical data from state Synar reports can demonstrate to the Secretary the national progress in reducing youth tobacco access problems. This information will also provide Congress with a better understanding of state progress in implementing Synar, including state difficulties and successes in enforcing retailer compliance with youth tobacco access laws.

---

<sup>1</sup>The term “state” is used to refer to all the states and territories required to comply with Synar as part of the Substance Abuse Prevention and Treatment Block Grant Program requirements (42 U.S.C. 300x-64 and 45 C.F.R. 96.121).

## Getting assistance in completing the Synar report

If you have questions about programmatic issues, you may call CSAP's Division of State Programs at (240) 276-2550 and ask for your respective State Project Officer, or contact your State Project Officer directly by telephone or email. If you have questions about fiscal or grants management issues, you may call the Grants Management Officer, Office of Financial Resources, Division of Grants Management, at (240) 276-1422.

## Where and when to submit the Synar report

The ASR must be received by SAMHSA no later than December 31, 2021 and must be submitted in the format specified by these instructions. Use of the approved format will avoid delays in the review and approval process. The chief executive officer (or an authorized designee) of the applicant organization must sign page one of the ASR certifying that the state has complied with all reporting requirements.

The state must upload one copy of the ASR using the online WebBGAS (Block Grant Application System). In addition, the following items must be uploaded to WebBGAS:

- FFY 2022 Synar Survey Results: States that use the Synar Survey Estimation System (SSES) must upload one copy of *SSES Tables 1–8* (in Excel) to WebBGAS. **Please note that, in the FFY 2022 ASR, SSES will generate Tables 6, 7, and 8, which are based on the optional microdata on product type, retail outlet type, and whether identification was requested. If your state does not submit these optional data, Tables 6, 7, and 8 will be blank. Tables 6, 7, and 8 are generated for the convenience of the state, and states are not required to submit completed versions of Tables 6, 7, or 8.** States that do not use SSES must upload one copy of ASR Forms 1, 4, and 5, and Forms 2 and 3, if applicable, (in Excel), as well as a database with the raw inspection data to WebBGAS.
- Synar Inspection Form: States must upload one blank copy of the inspection form used to record the result of each Synar inspection.
- Synar Inspection Protocol: States must upload a copy of the protocol used to train inspection teams on conducting and reporting the results of the Synar inspections. This document should be different than the Appendix C attached to the Annual Synar Report.
- A scanned copy of the signed Funding Agreements/Certifications

Each state SSA Director has been emailed a login ID and password to log onto the Synar section of the WebBGAS site.

## FFY 2022: FUNDING AGREEMENTS/CERTIFICATIONS

The following form must be signed by the Chief Executive Officer or an authorized designee and submitted with this application. Documentation authorizing a designee must be attached to the application.

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| <b>PUBLIC HEALTH SERVICES ACT AND SYNAR AMENDMENT</b>                                                                                                                                                                                                                                                                                                                                                                                                                              |                         |
| 42 U.S.C. 300x-26 requires each state to submit an annual report of its progress in meeting the requirements of the Synar Amendment and its implementing regulation (45 C.F.R. 96.130) to the Secretary of the Department of Health and Human Services. By signing below, the chief executive officer (or an authorized designee) of the applicant organization certifies that the state has complied with these reporting requirements and the certifications as set forth below. |                         |
| <b>SYNAR SURVEY SAMPLING METHODOLOGY</b>                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         |
| The state certifies that the Synar survey sampling methodology on file with the Center for Substance Abuse Prevention and submitted with the Annual Synar Report for FFY 2022 is up-to-date and approved by the Center for Substance Abuse Prevention.                                                                                                                                                                                                                             |                         |
| <b>SYNAR SURVEY INSPECTION PROTOCOL</b>                                                                                                                                                                                                                                                                                                                                                                                                                                            |                         |
| The state certifies that the Synar Survey Inspection Protocol on file with the Center for Substance Abuse Prevention and submitted with the Annual Synar Report for FFY 2022 is up-to-date and approved by the Center for Substance Abuse Prevention.                                                                                                                                                                                                                              |                         |
| State: Guam                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                         |
| Name of Chief Executive Officer or Designee: Theresa C. Arriola                                                                                                                                                                                                                                                                                                                                                                                                                    |                         |
| Signature of CEO or Designee:                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                         |
| Title: <sup>Acting</sup> Director                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Date Signed: 12/01/2021 |
| If signed by a designee, a copy of the designation must be attached.                                                                                                                                                                                                                                                                                                                                                                                                               |                         |



**GUAM BEHAVIORAL  
HEALTH & WELLNESS  
CENTER**

790 Gov. Carlos G. Camacho Rd.  
Tamuning, Guam 96913  
TEL: (671) 647-5330  
FAX: (671) 649-6948

**LOURDES A. LEON GUERRERO**  
Governor  
**JOSHUA F. TENORIO**  
Lieutenant Governor

**THERESA C. ARRIOLA**  
Director  
**CARISSA E. PANGELINAN**  
Deputy Director

November 18, 2021

**MEMORANDUM**

To: The Honorable Lourdes A. Leon Guerrero,  
Governor of Guam

Via: John Junior Calvo, Governor's Chief of Staff

From: Theresa C. Arriola, Director 

Subject: Request for Designation of Acting Director


*Hafa Adai!*

This memo is in reference to my attached admin leave form to attend the 69<sup>th</sup> Pacific Island Health Officers' Association (PIHOA) Executive Board Meeting in Koror, Palau. I respectfully recommend the designation of **Deputy Director Carissa Pangelinan**, to serve as **Acting Director** during my leave of absence from November 29, 2021 through December 3, 2021.

Your favorable consideration of this request is greatly appreciated.

*Un Dangkolo Na Si Yu'os Ma'dse.*

APPROVED  / DISAPPROVED / /

  
**LOURDES A. LEON GUERRERO**  
Governor of Guam



**GUAM BEHAVIORAL  
HEALTH AND WELLNESS  
CENTER**

**LOURDES A. LEON GUERRERO**

Governor

**JOSHUA F. TENORIO**

Lieutenant Governor

790 Gov. Carlos G. Camacho Rd.

Tamuning, GU 96913

TEL: (671) 647-5330

FAX: (671) 649-6948

**THERESA C. ARRIOLA**

Director

**CARISSA E. PANGELINAN**

Deputy Director

November 24, 2021

**MEMORANDUM**

**To:** All GBHWC Staff  
**From:** THERESA C. ARRIOLA  
Director  
**Subject:** Designation of Acting Director

***Buenas yan Hafa Adai!***

Please be advised that I will be on leave from November 29, 2021 through December 3, 2021. During my absence, Deputy Director Carissa Pangelinan will be designated as Acting Director for our agency. She will oversee all matters and concerns accordingly.

Your full support and cooperation is greatly appreciated.

***Un Dangkolo Na Si Yu'os Ma'ase.***

**SECTION I: FFY 2021 (Compliance Progress)****YOUTH ACCESS LAWS, ACTIVITIES, AND ENFORCEMENT**

42 U.S.C. 300x-26 requires the states to report information regarding the sale/distribution of tobacco products to individuals under age 18.

- 1. Please indicate any changes or additions to the state tobacco statute(s) relating to youth access since the last reporting year. If any changes were made to the state law(s) since the last reporting year, please upload a copy of the state law to WebBGAS. (see 42 U.S.C. 300x-26).**

- a. Has there been a change in the minimum sale age for tobacco products?**

☐ Yes ☒ No

*If Yes, current minimum age:* ☐ 19 ☐ 20 ☐ 21

- b. Have there been any changes in state law that impact the state's protocol for conducting Synar inspections?**

☐ Yes ☒ No

*If Yes, indicate change. (Check all that apply.)*

- ☐ Changed to require that law enforcement conduct inspections of tobacco outlets  
☐ Changed to make it illegal for youth to possess, purchase or receive tobacco  
☐ Changed to require ID to purchase tobacco  
☐ Changed definition of tobacco products  
☐ Other change(s) (Please describe.) \_\_\_\_\_

- c. Have there been any changes in state law that impact the following?**

Licensing of tobacco vendors ☐ Yes ☒ No

Penalties for sales to minors ☐ Yes ☒ No

Vending machines ☐ Yes ☒ No

Added product categories to youth access law ☐ Yes ☒ No

- 2. Describe how the Annual Synar Report (see 45 C.F.R. 96.130(e)) was made public within the state prior to submission of the ASR. (Check all that apply.)**

☐ Placed on file for public review

☒ Posted on a state agency Web site (Please provide exact Web address and the date when the FFY 2022 ASR was posted to this Web address.)

Web address: [www.gbhwv.guam.gov](http://www.gbhwv.guam.gov) & [www.peaceguam.org](http://www.peaceguam.org)

Date published: 12/07/2021

☐ Notice published in a newspaper or newsletter

☐ Public hearing

- ☐ Announced in a news release, a press conference, or discussed in a media interview
- ☐ Distributed for review as part of the SABG application process
- ☐ Distributed through the public library system
- ☐ Published in an annual register
- ☐ Other (Please describe.) \_\_\_\_\_

**3. Identify the following agency or agencies (see 42 U.S.C. 300x-26 and 45 C.F.R. 96.130).**

**a. The state agency(ies) designated by the Governor for oversight of the Synar requirements:**

Guam Behavioral Health and Wellness Center (GBHWC)

Has this changed since last year's Annual Synar Report?

☐ Yes ☒ No

**b. The state agency(ies) responsible for conducting random, unannounced Synar inspections:**

Guam Behavioral Health and Wellness Center and the Guam Department of Revenue and Taxation (DRT)

Has this changed since last year's Annual Synar Report?

☐ Yes ☒ No

**c. The state agency(ies) responsible for enforcing youth tobacco access law(s):**

Guam Department of Revenue and Taxation

Has this changed since last year's Annual Synar Report?

☐ Yes ☒ No

**4. Identify the following agencies and describe their relationship with the agency responsible for the oversight of the Synar requirements.**

**a. Identify the state agency responsible for tobacco prevention activities (the agency that receives the Centers for Disease Control and Prevention's National Tobacco Control Program funding).**

Guam Department of Public Health and Social Services (DPHSS) and Guam Behavioral Health and Wellness Center (GBHWC).

**b. Has the responsible agency changed since last year's Annual Synar Report?**

☐ Yes ☒ No

**c. Describe the coordination and collaboration that occur between the agency responsible for tobacco prevention and the agency responsible for oversight of the Synar requirements. (Check all that apply.) The two agencies**

☐ Are the same

- ☐ Have a formal written memorandum of agreement
- ☒ Have an informal partnership
- ☒ Conduct joint planning activities
- ☒ Combine resources
- ☒ Have other collaborative arrangement(s) *(Please describe.)* GBHWC continues to work in collaboration with other partnering agencies in the Governor's PEACE Council, Department of Public Health and Social Services (DPHSS) is an active member of the PEACE Council and leads the Non-Communicable Disease Consortium (NCD). GBHWC participates in the NCD Consortium to strengthen Guam's comprehensive state plans for mental health promotion and the prevention of substance abuse, suicide and other deaths resulting from NCD's. In turn, one of DPHSS priorities include Tobacco Prevention and Control Program (TCAT) which leads the NCD tobacco action team.
- ☐ No relationship

**d. Does a state agency contract with the Food and Drug Administration's Center for Tobacco Products (FDA/CTP) to enforce the youth access and advertising restrictions in the Family Smoking Prevention and Tobacco Control Act?**  
☒ Yes   ☐ No (if no, go to Question 5)

**e. If yes, identify the state agency responsible for enforcing the youth access and advertising restrictions in the Family Smoking Prevention and Tobacco Control Act (the agency that is under contract to the Food and Drug Administration's Center for Tobacco Products (FDA/CTP)).**  
GBHWC's, Director's Office

**f. Has the responsible agency changed since last year's Annual Synar Report?**  
☐ Yes   ☒ No

**g. Describe the coordination and collaboration that occur between the agency contracted with the FDA to enforce federal youth tobacco access laws and the agency responsible for oversight of the Synar requirements. (Check all that apply.) The two agencies:**

- ☒ Are the same
- ☐ Have a formal written memorandum of agreement
- ☐ Have an informal partnership
- ☐ Conduct joint planning activities
- ☒ Combine resources
- ☐ Have other collaborative arrangement(s) *(Please describe.)* \_\_\_\_\_
- ☐ No relationship

**h. Does the state use data from the FDA enforcement inspections for Synar survey reporting?**  
☐ Yes   ☒ No

**5. Please answer the following questions regarding the state's activities to enforce the state's youth access to tobacco law(s) in FFY 2021 (see 42 U.S.C. 300x-26 and 45 C.F.R. 96.130(e)).**

**a. Which one of the following describes the enforcement of state youth access to tobacco laws carried out in your state? (Check one category only.)**

- ☐ Enforcement is conducted exclusively by local law enforcement agencies.
- ☒ Enforcement is conducted exclusively by state agency(ies).
- ☐ Enforcement is conducted by both local *and* state agencies.

- b. The following items concern penalties imposed for all violations of state youth access to tobacco laws by **LOCAL AND/OR STATE LAW ENFORCEMENT AGENCIES** (this does not include enforcement of local laws or federal youth tobacco access laws). Please fill in the number requested. If state law does not allow for an item, please mark "NA" (not applicable). If a response for an item is unknown, please mark "UNK." The chart must be filled in completely.

| PENALTY                                     | OWNERS | CLERKS | TOTAL |
|---------------------------------------------|--------|--------|-------|
| Number of <u>citations issued</u>           | 31     |        | 31    |
| Number of <u>finest assessed</u>            | 31     |        | 31    |
| Number of <u>permits/licenses suspended</u> |        |        |       |
| Number of <u>permits/licenses revoked</u>   |        |        |       |
| Other (Please describe.)                    |        |        |       |

- c. Are citations or warnings issued to retailers or clerks who sell tobacco to minors for inspections that are part of the Synar survey?

☒ Yes ☐ No

If "Yes" to 5c, please describe the state's procedure for minimizing risk of bias to the survey results from retailers alerting each other to the presence of the survey teams:

In order to minimize the risk of bias from retailers alerting each other to the presence of survey teams, GBHWC utilizes multiple survey teams to conduct simultaneous inspections. In addition, not all stores are inspected on the same day. Stores to be inspected are divided up so that inspections occur on different days.

- d. Which one of the following best describes the level of enforcement of state youth access to tobacco laws carried out in your state? (Check one category only.)

- ☐ Enforcement is conducted only at those outlets randomly selected for the Synar survey.
- ☐ Enforcement is conducted only at a subset of outlets not randomly selected for the Synar survey.
- ☒ Enforcement is conducted at a combination of outlets randomly selected for the Synar survey and outlets not randomly selected for the Synar survey.

- e. Did every tobacco outlet in the state receive at least one compliance check that included enforcement of the state youth tobacco access law(s) in the last year?

☐ Yes ☒ No

- f. What additional activities are conducted in your state to support enforcement and compliance with state youth tobacco access law(s)? (Check all that apply and briefly describe each activity in the text boxes below each activity.)

☒ Merchant education and/or training

GBHWC's Prevention and Training Branch and the Department of Revenue and Taxation jointly coordinate and conduct merchant and community education. Both agencies are responsible for coordinating random, unannounced Synar inspections. During compliance inspections, retailers are provided with merchant education packets and other merchant materials such as door and register sticker signs displaying "P.L. 34-01 No Sale Under 21" annually GBHWC produces and distributes merchant educational and awareness materials in a packet to 350+ licensed tobacco vendors that: 1) includes information on Guam's youth access laws and federal law regarding sale of tobacco to persons under the age of 21. 2) provides specific strategies for how they can comply with Guam youth access laws; and 3) highlights the health effects of tobacco use.

- ☒ Incentives for merchants who are in compliance (e.g., nonenforcement compliance checks in which compliant retailers are given positive reinforcement and noncompliant retailers are warned about youth access laws)

A certificate of compliance signed by the directors of GBHWC and DRT is immediately issued to retailers who passed the inspection.

- ☒ Community education regarding youth access laws

- a) GBHWC continues to support 1) tobacco control policy efforts to decrease youth access and increase cessation services to at-risk populations in the community; and 2) education, disseminations and environmental activities used to prevent tobacco sales to minors.
- b) Continue to conduct annual compliance inspections required by Synar. Inspection teams to include youth are required to attend prior protocols training that include rules, regulations, basic procedures and paper work required to be completed.

- ☐ Media use to publicize compliance inspection results

- ☒ Community mobilization to increase support for retailer compliance with youth access laws

GBHWC Prevention and Training actively participate in all Guam's NCD Consortium activities and are members of the Tobacco Control Action Team (TCAT).

- ☒ Other activities (*Please list.*) \_\_\_\_\_

Continued partnerships and collaborations with community stakeholders around tobacco control and education.

## SYNAR SURVEY METHODS AND RESULTS

The following questions pertain to the survey methodology and results of the Synar survey used by the state to meet the requirements of the Synar Regulation in FFY 2021 (see 42 U.S.C. 300x-26 and 45 C.F.R. 96.130).

**6. Has the sampling methodology changed from the previous year?**

☐ Yes ☒ No

*The state is required to have an approved up-to-date description of the Synar sampling methodology on file with CSAP. Please submit a copy of your Synar Survey Sampling Methodology (Appendix B). If the sampling methodology changed from the previous reporting year, these changes must be reflected in the methodology submitted.*

**a. If yes, describe how and when this change was communicated to SAMHSA**

**7. Please answer the following questions regarding the state's annual random, unannounced inspections of tobacco outlets (see 45 C.F.R. 96.130(d)(2)).**

**a. Did the state use the optional Synar Survey Estimation System (SSES) to analyze the Synar survey data?**

☒ Yes ☐ No

*If Yes, upload a copy of SSES tables 1–8 (in Excel) to WebBGAS. Then go to Question 8. If No, continue to Question 7b.*

**b. Report the weighted and unweighted Retailer Violation Rate (RVR) estimates, the standard error, accuracy rate (number of eligible outlets divided by the total number of sampled outlets), and completion rate (number of eligible outlets inspected divided by the total number of eligible outlets).**

Unweighted RVR

Weighted RVR

Standard error (s.e.) of the (weighted) RVR

Fill in the blanks to calculate the right limit of the right-sided 95% confidence interval.

|              |      |        |       |                  |        |             |
|--------------|------|--------|-------|------------------|--------|-------------|
|              | +    | (1.645 | ×     | )                | =      |             |
| RVR Estimate | plus | (1.645 | times | Standard Error ) | equals | Right Limit |

Accuracy rate

Completion rate

c. **Fill out Form 1 in Appendix A (Forms 1–5).** (*Required regardless of the sample design.*)

d. **How were the (weighted) RVR estimate and its standard error obtained?**  
(*Check the one that applies.*)

☐ Form 2 (Optional) in Appendix A (Forms 1–5) (*Attach completed Form 2.*)

☐ Other (*Please specify. Provide formulas and calculations or attach and explain the program code and output with description of all variable names.*)

e. **If stratification was used, did any strata in the sample contain only one outlet or cluster this year?**

☐ Yes ☐ No ☐ No stratification

*If Yes, explain how this situation was dealt with in variance estimation.*

f. **Was a cluster sample design used?**

☐ Yes ☐ No

*If Yes, fill out and attach Form 3 in Appendix A (Forms 1–5), and answer the following question.*

*If No, go to Question 7g.*

**Were any certainty primary sampling units selected this year?**

☐ Yes ☐ No

*If Yes, explain how the certainty clusters were dealt with in variance estimation.*

g. **Report the following outlet sample sizes for the Synar survey.**

|                                                                                                                                                | Sample Size |
|------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| <b>Effective sample size</b> (sample size needed to meet the SAMHSA precision requirement assuming simple random sampling)                     |             |
| <b>Target sample size</b> (the product of the effective sample size and the design effect)                                                     |             |
| <b>Original sample size</b> (inflated sample size of the target sample to counter the sample attrition due to ineligibility and noncompletion) |             |
| <b>Eligible sample size</b> (number of outlets found to be eligible in the sample)                                                             |             |
| <b>Final sample size</b> (number of eligible outlets in the sample for which an inspection was completed)                                      |             |

h. **Fill out Form 4 in Appendix A (Forms 1–5).**

**8. Did the state's Synar survey use a list frame?**

☒ Yes ☐ No

*If Yes, answer the following questions about its coverage.*

a. The calendar year of the latest Sampling frame coverage study: 2011

b. Percent coverage from the latest Sampling frame coverage study: 98.3%

c. Was a new study conducted in this reporting period?

☐ Yes ☒ No

*If Yes, please complete Appendix D (List Sampling Frame Coverage Study) and submit it with the Annual Synar Report.*

d. The calendar year of the next coverage study planned: See response on section D waiver approved by SAMHSA on 6/14/2013 for FFY 2014 ASR

**9. Has the Synar survey inspection protocol changed from the previous year?**

☐ Yes ☒ No

*The state is required to have an approved up-to-date description of the Synar inspection protocol on file with CSAP. Please submit a copy of your Synar Survey Inspection Protocol (Appendix C). If the inspection protocol changed from the previous year, these changes must be reflected in the protocol submitted.*

a. If Yes, describe how and when this change was communicated to SAMHSA

b. Provide the inspection period: From 06/26/21 to 07/17/21  
MM/DD/YY MM/DD/YY

c. Provide the number of youth inspectors used in the current inspection year:

11

NOTE: If the state uses SSES, please ensure that the number reported in 9b matches that reported in SSES Table 4, or explain any difference.

d. Fill out and attach Form 5 in Appendix A (Forms 1–5). (Not required if the state used SSES to analyze the Synar survey data.)

## SECTION II: FFY 2022 (Intended Use):

Public Law 42 U.S.C. 300x-26 of the Public Health Service Act and 45 C.F.R. 96.130 (e) (4, 5) require that the states provide information on future plans to ensure compliance with the Synar requirements to reduce youth tobacco access.

**1. In the upcoming year, does the state anticipate any changes in:**

Synar sampling methodology ☐ Yes ☒ No

Synar inspection protocol ☐ Yes ☒ No

*If changes are made in either the Synar sampling methodology or the Synar inspection protocol, the state is required to obtain approval from CSAP prior to implementation of the change and file an updated Synar Survey Sampling Methodology (Appendix B) or an updated Synar Survey Inspection Protocol (Appendix C), as appropriate.*

**2. Please describe the state's plans to maintain and/or reduce the target rate for Synar inspections to be completed in FFY 2022. Include a brief description of plans for law enforcement efforts to enforce youth tobacco access laws, activities that support law enforcement efforts to enforce youth tobacco access laws, and any anticipated changes in youth tobacco access legislation or regulation in the state.**

Public Law 34-01- AN ACT TO AMMEND §6101(1) OF ARTICLE 1: §6302 OF ARTICLE 3: AND ARTICLE 4, ALL OF CHAPTER 6, TITLE 11, GUAM CODE ANNOTATED, RELATIVE TO CLARIFYING THE DEFINITION OF ELECTRONIC CIGARETTES, AND RAISING THE MINIMUM AGE OF LEGAL ACCESS TO TOBACCO PRODUCTS AND ELECTRONIC CIGARETTES TO TWENTY-ONE (21) YEARS: AND TO CITE THIS ACT AS THE "YOUTH PROTECTION ACT OF 2017" (Bill No. 9-34 (COR), Sponsor: B.J.F. Cruz | Passed: 3/09/17 – Lapsed into Law 3/24/17.

Public Law 34-35 "AN ACT TO ADD NEW ARTICLES 7 & 8 TO CHAPTER 6, TITLE 11, GUAM CODE ANNOTATED, RELATIVE TO DEFINING THE STAMP TAX ON CIGARETTES AND REQUIRING FOR THE PROPER AFFIXING OF STAMPS; AND AUTHORIZING THE DEPARTMENT OF REVENUE AND TAXATION TO PROMUGATE IMPLEMENTING REGULATIONS, "Bill No. 77-34 (COR) which lapsed into law on October 14, 2017.

Public Law 34-116 "AN ACT MAKING APPROPRIATIONS FOR THE OPERATIONS OF THE EXECUTIVE, LEGISLATIVE AND JUDICIAL BRANCHES OF THE GOVERNMENT OF GUAM FOR FISCAL YEAR ENDING SEPTEMBER 30, 2019, MAKING OTHER APPROPRIATIONS, AND ESTABLISHING MISCELLANEOUS AND ADMINISTRATIVE PROVISIONS, "Bill No. 323-34 (COR) was on the 11<sup>th</sup> day of August 2018, duly and regularly passed. Section 4 Tobacco Tax Increase, Subsections (a), (b) and (c) of § 26603, Article 6, Chapter 26, Title 11, Guam Code Annotated are hereby amended.

Bill 199-34 Relative to increasing the tobacco tax for prevention cessation, and data collection relative to tobacco use. This Act shall take effect 30 days after ratification by the voters of Guam in a referendum during the 2018 General Election.

P.L.35-47 (Bill No. 138-35) (COR) AN ACT TO AMEND § 90103 OF CHAPTER 90, TITLE 10, GUAM CODE ANNOTATED, RELATIVE TO EXPANDING THE *NATASHA PROTECTION ACT OF 2005* TO DEFINE AND PROHIBIT THE USE OF ELECTRONIC SMOKING DEVICES WHEREVER OTHER TOBACCO PRODUCTS ARE ALREADY PROHIBITED.

Successes that affect the youth: Continue to provide the Guam Department of Education with tobacco cessation trainings and printed resource materials to help users.

Community Empowerment successes: Continue to provide trainings to communities; a) Tobacco Control Enforcers Training; b) Brief Tobacco Intervention Skills certification; c) Tobacco Cessation Facilitator Training.

Community Engagement successes; Continue to conduct annual Synar compliance inspection.

**3. Describe any challenges the state faces in complying with the Synar regulation. (Check all that apply and describe each challenge in the text box below it.)**

☐ Limited resources for law enforcement of youth access laws

☐ Limited resources for activities to support enforcement and compliance with youth tobacco access laws

☐ Limitations in the state youth tobacco access laws

☐ Limited public support for enforcement of youth tobacco access laws

☐ Limitations on completeness/accuracy of list of tobacco outlets

☐ Limited expertise in survey methodology

- ☐ Laws/regulations limiting the use of minors in tobacco inspections

- ☒ Difficulties recruiting youth inspectors

GBHWC experienced difficulties in recruiting youth inspectors due to COVID-19 pandemic.

- ☐ Issues regarding the balance of inspections conducted by youth inspectors age 15 and under

- ☒ Issues regarding the balance of inspections conducted by one gender of youth inspectors

GBHWC experienced difficulties in recruiting youth inspectors that were male due to COVID-19 pandemic.

- ☐ Geographic, demographic, and logistical considerations in conducting inspections

- ☐ Cultural factors (e.g., language barriers, young people purchasing for their elders)

- ☐ Issues regarding sources of tobacco under tribal jurisdiction

- ☒ Other challenges (*Please list.*)

Due to the COVID-19 Pandemic, GBHWC experienced challenges in completing all the inspections

## APPENDIX A: FORMS 1–5

### **FORM 1 (Required for all states not using the Synar Survey Estimation System (SSES) to analyze the Synar Survey data)**

Complete Form 1 to report sampling frame and sample information and to calculate the unweighted retailer violation rate (RVR) using results from the current year's Synar survey inspections.

**Instructions for Completing Form 1:** In the top right-hand corner of the form, provide the state name and reporting federal fiscal year (FFY 2022). Provide the remaining information by stratum if stratification was used. Make copies of the form if additional rows are needed to list all the strata.

**Column 1:** *If stratification was used:*

1(a) Sequentially number each row.

1(b) Write in the name of each stratum. All strata in the state must be listed.

*If no stratification was used:*

1(a) Leave blank.

1(b) Write "state" in the first row (indicates that the whole state is a single stratum).

*Note for unstratified samples: For Columns 2–5, wherever the instruction refers to "each stratum," report the specified information for the state as a whole.*

**Column 2:** 2(a) Report the number of over-the-counter (OTC) outlets in the sampling frame in each stratum.  
2(b) Report the number of vending machine (VM) outlets in the sampling frame in each stratum.  
2(c) Report the combined total of OTC and VM outlets in the sampling frame in each stratum.

**Column 3:** 3(a) Report the estimated number of eligible OTC outlets in the OTC outlet population in each stratum.  
3(b) Report the estimated number of eligible VM outlets in the VM outlet population in each stratum.  
3(c) Report the combined total estimated number of eligible OTC and VM outlets in the total outlet population in each stratum.

*The estimates for Column 3 can be obtained from the Synar survey sample as the weighted sum of eligible outlets by outlet type.*

**Column 4:** 4(a) Report the number of eligible OTC outlets for which an inspection was completed, for each stratum.  
4(b) Report the numbers of eligible VM outlets for which an inspection was completed, for each stratum.  
4(c) Report the combined total of eligible OTC and VM outlets for which an inspection was completed, for each stratum.

**Column 5:** 5(a) Report the number of OTC outlets found in violation of the law as a result of completed inspections, for each stratum.  
5(b) Report the number of VM outlets found in violation of the law as a result of completed inspections, for each stratum.  
5(c) Report the combined total of OTC and VM outlets found in violation of the law as a result of completed inspections, for each stratum.

**Totals:** For each subcolumn (a–c) in Columns 2–5, provide totals for the state as a whole in the last row of the table. These numbers will be the sum of the numbers in each row for the respective column.

[illegible]

RECORD COLUMN TOTALS ON LAST LINE (LAST PAGE ONLY IF MULTIPLE PAGES ARE NEEDED).

**FORM 2 (Optional)**

**Appropriate for stratified simple or systematic random sampling designs.**

Complete Form 2 to calculate the weighted RVR. This table (in Excel form) is designed to calculate the weighted RVR for stratified simple or systematic random sampling designs, accounting for ineligible outlets and noncomplete inspections encountered during the annual Synar survey.

**Instructions for Completing Form 2:** In the top right-hand corner of the form, provide the state name and reporting federal fiscal year (FFY 2022).

- Column 1: Write in the name of each stratum into which the sample was divided. These should match the strata reported in Column 1(b) of Form 1.
- Column 2: Report the number of outlets in the sampling frame in each stratum. These numbers should match the numbers reported for the respective strata in Column 2(c) of Form 1.
- Column 3: Report the original sample size (the number of outlets originally selected, *including* substitutes or replacements) for each stratum.
- Column 4: Report the number of sample outlets in each stratum that were found to be eligible during the inspections. Note that this number must be less than or equal to the number reported in Column 3 for the respective strata.
- Column 5: Report the number of eligible outlets in each stratum for which an inspection was completed. Note that this number must be less than or equal to the number reported in Column 4. These numbers should match the numbers reported in Column 4(c) of Form 1 for the respective strata.
- Column 6: Report the number of eligible outlets inspected in each stratum that were found in violation. These numbers should match the numbers reported in Column 5(c) of Form 1 for the stratum.
- Column 7: Form 2 (in Excel form) will automatically calculate the stratum RVR for each stratum in this column. This is calculated by dividing the number of inspected eligible outlets found in violation (Column 6) by the number of inspected eligible outlets (Column 5). The state unweighted RVR will be shown in the Total row of Column 7.
- Column 8: Form 2 (in Excel form) will automatically calculate the estimated number of eligible outlets in the population for each stratum. This calculation is made by multiplying the number of outlets in the sampling frame (Column 2) times the number of eligible outlets (Column 4) divided by the original sample size (Column 3). Note that these numbers will be less than or equal to the numbers in Column 2.
- Column 9: Form 2 (in Excel form) will automatically calculate the relative stratum weight by dividing the estimated number of eligible outlets in the population for each stratum in Column 8 by the Total of the values in Column 8.
- Column 10: Form 2 (in Excel form) will automatically calculate each stratum's contribution to the state weighted RVR by multiplying the stratum RVR (Column 7) by the relative stratum weight (Column 9). The weighted RVR for the state will be shown in the Total row of Column 10.
- Column 11: Form 2 (in Excel form) automatically calculates the standard error of each stratum's RVR (Column 7). The standard error for the state weighted RVR will be shown in the Total row of Column 11.
- TOTAL:** For Columns 2–6, Form 2 (in Excel form) provides totals for the state as a whole in the last row of the table. For Columns 7–11, it calculates the respective statistic for the state as a whole.

**FORM 2 (Optional) Appropriate for stratified simple or systematic random sampling designs.**

| Calculation of Weighted Retailer Violation Rate |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|-------------------------------------------------|----------------------------------------------------------|-------------------------------------|------------------------------------------------------------------|------------------------------------------------|-----------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------|
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      | State: _____                                        |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      | FFY: 2022                                           |
| (1)<br>Stratum<br>Name                          | (2)<br>N<br>Number of<br>Outlets<br>in Sampling<br>Frame | (3)<br>n<br>Original<br>Sample Size | (4)<br>n1<br>Number of<br>Sample<br>Outlets<br>Found<br>Eligible | (5)<br>n2<br>Number of<br>Outlets<br>Inspected | (6)<br>x<br>Number of<br>Outlets<br>Found<br>in Violation | (7)<br>$p=x/n2$<br>Stratum<br>Retailer<br>Violation<br>Rate | (8)<br>$N'=N(n1/n)$<br>Estimated<br>Number of<br>Eligible<br>Outlets in<br>Population | (9)<br>$w=N'/\text{Total}$<br>Column 8<br>Relative<br>Stratum<br>Weight | (10)<br>pw<br>Stratum<br>Contribution<br>to State<br>Weighted<br>RVR | (11)<br>s.e.<br>Standard<br>Error of<br>Stratum RVR |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
|                                                 |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |
| <b>Total</b>                                    |                                                          |                                     |                                                                  |                                                |                                                           |                                                             |                                                                                       |                                                                         |                                                                      |                                                     |

N - number of outlets in sampling frame  
 n - original sample size (number of outlets in the original sample)  
 n1 - number of sample outlets that were found to be eligible  
 n2 - number of eligible outlets that were inspected  
 x - number of inspected outlets that were found in violation  
 p - stratum retailer violation rate ( $p=x/n2$ )  
 N' - estimated number of eligible outlets in population ( $N'=N*n1/n$ )  
 w - relative stratum weight ( $w=N'/\text{Total Column 8}$ )  
 pw - stratum contribution to the weighted RVR  
 s.e. - standard error of the stratum RVR

**FORM 3 (Required when a cluster design is used for all states not using the Synar Survey Estimation System [SSES] to analyze the Synar survey data.)**

Complete Form 3 to report information about primary sampling units when a cluster design was used for the Synar survey.

**Instructions for Completing Form 3:** In the top right-hand corner of the form, provide the state name and reporting federal fiscal year (FFY 2022).

Provide information by stratum if stratification was used. Make copies of the form if additional rows are needed to list all the strata.

Column 1: Sequentially number each row.

Column 2: *If stratification was used:* Write in the name of stratum. All strata in the state must be listed.

*If no stratification was used:* Write "state" in the first row to indicate that the whole state constitutes a single stratum.

Column 3: Report the number of primary sampling units (PSUs) (i.e., first-stage clusters) created for each stratum.

Column 4: Report the number of PSUs selected in the original sample for each stratum.

Column 5: Report the number of PSUs in the final sample for each stratum.

TOTALS: For Columns 3–5, provide totals for the state as a whole in the last row of the table.

| Summary of Clusters Created and Sampled |                     |                                  |                                   |                                                 |
|-----------------------------------------|---------------------|----------------------------------|-----------------------------------|-------------------------------------------------|
| State: _____                            |                     |                                  |                                   |                                                 |
| FFY: 2022                               |                     |                                  |                                   |                                                 |
| (1)<br>Row #                            | (2)<br>Stratum Name | (3)<br>Number of PSUs<br>Created | (4)<br>Number of PSUs<br>Selected | (5)<br>Number of PSUs<br>in the Final<br>Sample |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
|                                         |                     |                                  |                                   |                                                 |
| Total                                   |                     |                                  |                                   |                                                 |

**FORM 4 (Required for all states not using the Synar Survey Estimation System [SSES] to analyze the Synar Survey data)**

Complete Form 4 to provide detailed tallies of ineligible sample outlets by reasons for ineligibility and detailed tallies of eligible sample outlets with noncomplete inspections by reasons for noncompletion.

**Instructions for Completing Form 4:** In the top right-hand corner of the form, provide the state name and reporting federal fiscal year (FFY 2022).

Column 1(a): Enter the number of sample outlets found ineligible for inspection by reason for ineligibility. Provide the total number of ineligible outlets in the row marked "Total."

Column 2(a): Enter the number of eligible sample outlets with noncomplete inspections by reason for noncompletion. Provide the total number of eligible outlets with noncomplete inspections in the row marked "Total."

| <b>Inspection Tallies by Reason of Ineligibility or Noncompletion</b><br><b>State:</b> _____<br><b>FFY: 2022</b> _____ |                       |                                                         |                       |
|------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------------------------------------------|-----------------------|
| <b>(1)<br/>INELIGIBLE</b>                                                                                              |                       | <b>(2)<br/>ELIGIBLE</b>                                 |                       |
| <b>Reason for Ineligibility</b>                                                                                        | <b>(a)<br/>Counts</b> | <b>Reason for Noncompletion</b>                         | <b>(a)<br/>Counts</b> |
| Out of business                                                                                                        |                       | In operation but closed at time of visit                |                       |
| Does not sell tobacco products                                                                                         |                       | Unsafe to access                                        |                       |
| Inaccessible by youth                                                                                                  |                       | Presence of police                                      |                       |
| Private club or private residence                                                                                      |                       | Youth inspector knows salesperson                       |                       |
| Temporary closure                                                                                                      |                       | Moved to new location                                   |                       |
| Unlocatable                                                                                                            |                       | Drive-thru only/youth inspector has no driver's license |                       |
| Wholesale only/Carton sale only                                                                                        |                       | Tobacco out of stock                                    |                       |
| Vending machine broken                                                                                                 |                       | Ran out of time                                         |                       |
| Duplicate                                                                                                              |                       | Other noncompletion reason(s) ( <i>Describe.</i> )      |                       |
| Other ineligibility reason(s) ( <i>Describe.</i> )                                                                     |                       |                                                         |                       |
| <b>Total</b>                                                                                                           |                       | <b>Total</b>                                            |                       |

**FORM 5 (Required for all states not using the Synar Survey Estimation System [SSES] to analyze the Synar survey data)**

Complete Form 5 to show the distribution of outlet inspection results by age and gender of the youth inspectors.

**Instructions for Completing Form 5:** In the top right-hand corner of the form, provide the state name and reporting federal fiscal year (FFY 2022).

Column 1: Enter the number of attempted buys by youth inspector age and gender.

Column 2: Enter the number of successful buys by youth inspector age and gender.

If the inspectors are age eligible but the gender of the inspector is unknown, include those inspections in the "Other" row. Calculate subtotals for males and females in rows marked "Male Subtotal" and "Female Subtotal." Sum subtotals for Male, Female, and Other and record in the bottom row marked "Total." Verify that that the total of attempted buys and successful buys equals the total for Column 4(c) and Column 5(c), respectively, on Form 1. If the totals do not match, please explain any discrepancies.

| Synar Survey Inspector Characteristics |                       |                        |
|----------------------------------------|-----------------------|------------------------|
|                                        |                       | State: <u>Guam</u>     |
|                                        |                       | FFY: <u>2022</u>       |
|                                        | (1)<br>Attempted Buys | (2)<br>Successful Buys |
| <b>Male</b>                            |                       |                        |
| 15 years                               |                       |                        |
| 16 years                               |                       |                        |
| 17 years                               |                       |                        |
| 18 years                               |                       |                        |
| 19 years                               |                       |                        |
| 20 years                               |                       |                        |
| <b>Male Subtotal</b>                   |                       |                        |
| <b>Female</b>                          |                       |                        |
| 15 years                               |                       |                        |
| 16 years                               |                       |                        |
| 17 years                               |                       |                        |
| 18 years                               |                       |                        |
| 19 years                               |                       |                        |
| 20 years                               |                       |                        |
| <b>Female Subtotal</b>                 |                       |                        |
| <b>Other</b>                           |                       |                        |
| <b>Total</b>                           |                       |                        |

## **APPENDIXES B & C: FORMS**

### **Instructions**

Appendix B (Sampling Design) and Appendix C (Inspection Protocol) are to reflect the state's CSAP-approved sampling design and inspection protocol. These appendixes, therefore, should generally describe the design and protocol and, with the exception of Question #10 of Appendix B, are not to be modified with year-specific information. Please note that any changes to either appendix must receive CSAP's advance, written approval. To facilitate the state's completion of this section, simply cut and paste the previously approved sampling design (Appendix B) and inspection protocol (Appendix C) and respond to Question #10 of Appendix B to provide the requested information about sample size calculations for the Synar survey conducted in FFY 2021.

## APPENDIX B: SYNAR SURVEY SAMPLING METHODOLOGY

State: Guam

FFY: 2022

**1. What type of sampling frame is used?**

- ☒ List frame (*Go to Question 2.*)  
☐ Area frame (*Go to Question 3.*)  
☐ List-assisted area frame (*Go to Question 2.*)

**2. List all sources of the list frame. Indicate the type of source from the list below. Provide a brief description of the frame source. Explain how the lists are updated (method), including how new outlets are identified and added to the frame. In addition, explain how often the lists are updated (cycle). (After completing this question, go to Question 4.)**

*Use the corresponding number to indicate Type of Source in the table below.*

- |                                           |                                          |
|-------------------------------------------|------------------------------------------|
| 1 – Statewide commercial business list    | 4 – Statewide retail license/permit list |
| 2 – Local commercial business list        | 5 – Statewide liquor license/permit list |
| 3 – Statewide tobacco license/permit list | 6 – Other                                |

| Name of Frame Source | Type of Source | Description                                                                                                                                                                 | Updating Method and Cycle                                                                                                                                                                                              |
|----------------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Tobacco License List | 3              | Under Public Law 24-278, a tobacco vendor or store must obtain a tobacco vendor license from the Guam Department of Revenue and Taxation in order to sell tobacco products. | The owner of the establishment wishing to sell tobacco products must complete an initial tobacco business license application form Guam Revenue and Taxation's General Licensing Branch that must be renewed annually. |
|                      |                |                                                                                                                                                                             |                                                                                                                                                                                                                        |
|                      |                |                                                                                                                                                                             |                                                                                                                                                                                                                        |
|                      |                |                                                                                                                                                                             |                                                                                                                                                                                                                        |
|                      |                |                                                                                                                                                                             |                                                                                                                                                                                                                        |

**3. If an area frame is used, describe how area sampling units are defined and formed.**

**a. Is any area left out in the formation of the area frame?**

☐ Yes ☐ No

*If Yes, what percentage of the state's population is not covered by the area frame?*

\_\_\_\_\_%

**4. Federal regulation requires that vending machines be inspected as part of the Synar survey. Are vending machines included in the Synar survey?**

☐ Yes ☒ No

If No, please indicate the reason(s) they are not included in the Synar survey. Please check all that apply.

- ☐ State law bans vending machines.
- ☐ State law bans vending machines from locations accessible to youth.
- ☐ State has a contract with the FDA and is actively enforcing the vending machine requirements of the Family Smoking Prevention and Tobacco Control Act.
- ☒ Other (Please describe.) Public Law 34-01 § (a) vending machine selling tobacco products or electronic cigarettes shall be located so that they are only accessible to persons over the age of twenty-one (21) years, or are under constant, direct supervision and unobstructed line of sight of the person authorizing the installation or placement of the tobacco or electronic cigarette vending machine upon the premises he or she manages or otherwise controls, or his or her agent or employee. We have not seen vending machines selling tobacco products or electronic cigarettes here in Guam in the past 7 years.

If Yes, please indicate how likely it is that vending machines will be sampled.

- ☐ Vending machines are sampled separately to ensure vending machines are included in the sample
- ☐ Vending machines are sampled together with over the counter outlets, so it is possible that no vending machines were sampled, however they are included in the sampling frame and have a non-zero probability of selection
- ☐ Other reasons (Please describe.) \_\_\_\_\_

5. Which category below best describes the sample design? (Check only one.)

- ☒ **Census** (STOP HERE: Appendix B is complete.)

**Unstratified statewide sample:**

- ☐ Simple random sample (Go to Question 9.)
- ☐ Systematic random sample (Go to Question 6.)
- ☐ Single-stage cluster sample (Go to Question 8.)
- ☐ Multistage cluster sample (Go to Question 8.)

**Stratified sample:**

- ☐ Simple random sample (Go to Question 7.)
- ☐ Systematic random sample (Go to Question 6.)
- ☐ Single-stage cluster sample (Go to Question 7.)
- ☐ Multistage cluster sample (Go to Question 7.)
- ☐ Other (Please describe and go to Question 9.) \_\_\_\_\_

6. Describe the systematic sampling methods. (After completing Question 6, go to Question 7 if stratification is used. Otherwise go to Question 9.)

7. Provide the following information about stratification.

- a. Provide a full description of the strata that are created.

b. Is clustering used within the stratified sample?

☐ Yes (Go to Question 8.)

☐ No (Go to Question 9.)

8. Provide the following information about clustering.

a. Provide a full description of how clusters are formed. (If multistage clusters are used, give definitions of clusters at each stage.)

b. Specify the sampling method (simple random, systematic, or probability proportional to size sampling) for each stage of sampling and describe how the method(s) is (are) implemented.

9. Provide the following information about determining the Synar Sample.

a. Was the Synar Survey Estimation System (SSES) used to calculate the sample size?

☐ Yes (Respond to part b.)

☐ No (Respond to part c and Question 10c.)

b. SSES Sample Size Calculator used?

☐ State Level (Respond to Question 10a.)

☐ Stratum Level (Respond to Question 10a and 10b.)

c. Provide the formulas for determining the effective, target, and original outlet sample sizes.

10. Provide the following information about sample size calculations for the Synar survey conducted in FFY 2021.

a. If the state uses the sample size formulas embedded in the SSES Sample Size Calculator to calculate the state level sample size, please provide the following information:

Inputs for Effective Sample Size:

RVR:

Frame Size:

Input for Target Sample Size:

Design Effect:

**Inputs for Original Sample Size:**

Safety Margin:

Accuracy (Eligibility) Rate:

Completion Rate:

- b. If the state uses the sample size formulas embedded in the SSES Sample Size Calculator to calculate the stratum level sample sizes, please provide the stratum level information:**

|  |
|--|
|  |
|--|

- c. If the state does not use the sample size formulas embedded in the SSES Sample Size Calculator, please provide all inputs required to calculate the effective, target, and original sample sizes as indicated in Question 9.**

|  |
|--|
|  |
|--|

## APPENDIX C: SYNAR SURVEY INSPECTION PROTOCOL SUMMARY

State: Guam

FFY: 2022

*Note: Upload to WebBGAS a copy of the Synar inspection form under the heading "Synar Inspection Form" and a copy of the protocol used to train inspection teams on conducting and reporting the results of the Synar inspections under the heading "Synar Inspection Protocol."*

**1. How does the state Synar survey protocol address the following?**

**a. Consummated buy attempts?**

☒ Required

☐ Permitted under specified circumstances (Describe: \_\_\_\_\_)

☐ Not permitted

**b. Youth inspectors to carry ID?**

☐ Required

☐ Permitted under specified circumstances (Describe: \_\_\_\_\_)

☒ Not permitted

**c. Adult inspectors to enter the outlet?**

☒ Required

☐ Permitted under specified circumstances (Describe: \_\_\_\_\_)

☐ Not permitted

**d. Youth inspectors to be compensated?**

☒ Required

☐ Permitted under specified circumstances (Describe: \_\_\_\_\_)

☐ Not permitted

**2. Identify the agency(ies) or entity(ies) that actually conduct the random, unannounced Synar inspections of tobacco outlets. (Check all that apply.)**

☐ Law enforcement agency(ies)

☒ State or local government agency(ies) other than law enforcement

☐ Private contractor(s)

☒ Other

List the agency name(s): Guam Behavioral Health and Wellness Center, Guam Department of Revenue and Taxation and community volunteers.

3. Are Synar inspections combined with law enforcement efforts (i.e., do law enforcement representatives issue warnings or citations to retailers found in violation of the law at the time of the inspection)?

☒ Always   ☐ Usually   ☐ Sometimes   ☐ Rarely   ☐ Never

4. Describe the type of tobacco products that are requested during Synar inspections.

- a. What type of tobacco products are requested during the inspection?

- ☒ Cigarettes  
☐ Small Cigars  
☐ Cigarillos  
☐ Smokeless Tobacco  
☐ Electronic Cigarettes/Electronic Nicotine Delivery Systems (ENDS)  
☐ Other

- b. Describe the protocol for identifying what types of products and what brands of products are requested during an inspection.

During Synar training, Adult Enforcement Officers will choose a brand of cigarette that will be asked for during the inspections. Youth inspectors were also trained to list the products being offered by the establishment such as smokeless tobacco, cigars, electronic cigarettes. Cigarettes are still the most common form of tobacco sold in Guam.

- 5a. Describe the methods used to recruit, select, and train adult supervisors.

GBHWC's Prevention and Training Branch recruits' staff from GBHWC, Guam Department of Revenue and Taxation and the community to be trained as adult supervisors.

- 5b. Describe the methods used to recruit, select, and train youth inspectors.

Youth inspectors are recruited through youth organizations, groups, schools and through word of mouth.

6. Are there specific legal or procedural requirements instituted by the state to address the issue of youth inspectors' immunity when conducting inspections?

- a. Legal

☒ Yes   ☐ No

*(If Yes, please describe.)*

Stipulated in Section 6120 of Guam P.L., 24-278 states that "Participation in these enforcement activities by a minor shall not constitute a violation of Section 6 1 1 6 of this Chapter, and the minor is immune from prosecution or penalties thereunder,

or under any other provision of law prohibiting the purchase of these products by minors”.

**b. Procedural**

☒ Yes ☐ No

*(If Yes, please describe.)*

Guam's Manual of Procedures includes a section on "Legal Consolidations" which address issues related to confidentiality, protection of minors' identities, immunity for youth inspectors, and non-involvement of youth inspectors of legal proceedings arising from the inspections process.

**7. Are there specific legal or procedural requirements instituted by the state to address the issue of the safety of youth inspectors during all aspects of the Synar inspection process?**

**a. Legal**

☐ Yes ☒ No

*(If Yes, please describe.)*

**b. Procedural**

☒ Yes ☐ No

*(If Yes, please describe.)*

Guam's Manual of Procedures emphasizes the importance of ensuring the safety of youth inspectors throughout the inspection process. Specifically, youth inspectors are instructed to never venture into any establishment where they may feel unsafe, and to retreat immediately if upon entry into a store, they have a reason to feel uncomfortable or unsafe. In addition, Guam's Manual of Procedures make it mandatory for adult inspectors to always be within the vicinity of a youth inspector during an attempted buy.

**8. Are there any other legal or procedural requirements the state has regarding how inspections are to be conducted (e.g., age of youth inspector, time of inspections, training that must occur)?**

**a. Legal**

☒ Yes ☐ No

*(If Yes, please describe.)*

Guam P.L. 24-278 6120 outlines all of the legal requirements relating to the conduct of inspections, including the enlistment of youth inspectors from ages 12-17, the necessity for parental consent in writing, the right to use video recording equipment during inspections, the necessity to avoid entrapment by mandating all youth inspectors to answer truthfully when asked about their age, the need for adult supervision of all youth inspectors, and the role of the adult inspector in informing the vendor of non-compliance with the law after the youth inspector has left the premises.

Guam P.L. 34-01 (The Youth Protection Act of 2017) prohibits the sale of tobacco products to persons under 21 years of age.

**b. Procedural**

☒ Yes ☐ No

*(If Yes, please describe.)*

Guam's Manual of Procedures outlines in detail the requirements for inspection, consistent with the law and with recommended SAMHSA protocols. One item to note is that the Manual of Procedures prescribes the recruitment of youth inspectors aged 14-17, consistent with federal guidelines, although Guam's law allows for youth as young as 12 to participate.

Guam P.L. 34-01 (The Youth Protection Act of 2017) prohibits the sale of tobacco products to persons under 21 years of age. Guam now recruits youth inspectors from ages 15-20 years of age to participate in the Annual Synar Compliance Check Inspections.

## APPENDIX D: LIST SAMPLING FRAME COVERAGE STUDY

(LIST FRAME ONLY)

State: Guam

FFY: 2022

1. Calendar year of the coverage study: "SAMHSAA approved 'Complete waiver of the Synar coverage study requirement' on 6/14/2013"

2. a. Unweighted percent coverage found: \_\_\_\_\_ %  
b. Weighted percent coverage found: \_\_\_\_\_ %  
c. Number of outlets found through canvassing: \_\_\_\_\_  
d. Number of outlets matched on the list frame: \_\_\_\_\_

3. a. Describe how areas were defined. (e.g., census tracts, counties, etc.)

b. Were any areas of the state excluded from sampling?

☐ Yes ☐ No

If Yes, please explain.

4. Please answer the following questions about the selection of canvassing areas.

a. Which category below best describes the sample design? (Check only one.)

☐ Census (Go to Question 6.)

**Unstratified statewide sample:**

☐ Simple random sample (Respond to Part b.)

☐ Systematic random sample (Respond to Part b.)

☐ Single-stage cluster sample (Respond to Parts b and d.)

☐ Multistage cluster sample (Respond to Parts b and d.)

**Stratified sample:**

☐ Simple random sample (Respond to Parts b and c.)

☐ Systematic random sample (Respond to Parts b and c.)

☐ Single-stage cluster sample (Respond to Parts b, c, and d.)

☐ Multistage cluster sample (Respond to Parts b, c, and d.)

☐ Other (Please describe and respond to Part b.) \_\_\_\_\_

b. Describe the sampling methods.

- c. Provide a full description of the strata that were created.

- d. Provide a full description of how clusters were formed.

5. Were borders of the selected areas clearly identified at the time of canvassing?

☐ Yes ☐ No

6. Were all sampled areas visited by canvassing teams?

☐ Yes (*Go to Question 7.*) ☐ No (*Respond to Parts a and b.*)

- a. Was the subset of areas randomly chosen?

☐ Yes ☐ No

- b. Describe how the subsample of visited areas was drawn. Include the number of areas sampled and the number of areas canvassed.

7. Were field observers provided with a detailed map of the canvassing areas?

☐ Yes ☐ No

*If No, describe the canvassing instructions given to the field observers.*

8. Were field observers instructed to find all outlets in the assigned area?

☐ Yes ☐ No

*If No, respond to Question 9.*

*If Yes, describe any instructions given to the field observers to ensure the entire area was canvassed, then go to Question 10.*

9. If a full canvassing was not conducted:

- a. How many predetermined outlets were to be observed in each area? \_\_\_\_\_

- b. What were the starting points for each area? \_\_\_\_\_

- c. Were these starting points randomly chosen?

☐ Yes ☐ No

- d. Describe the selection of the starting points.

- e. Please describe the canvassing instructions given to the field observers, including predetermined routes.

10. Describe the process field observers used to determine if an outlet sold tobacco.

11. Please provide the state's definition of "matches" or "mismatches" to the Synar sampling frame? (i.e., address, business name, business license number, etc.)

12. Provide the calculation of the weighted percent coverage (if applicable).

**SSES Table 1 (Synar Survey Estimates and Sample Sizes)**

**CSAP-SYNAR REPORT**

|                           |                                   |
|---------------------------|-----------------------------------|
| State                     | GU                                |
| Federal Fiscal Year (FFY) | 2022                              |
| Date                      | 12/7/2021 11:50                   |
| Data                      | SSEsv7_DataEntryTemplate_SRS.xlsx |
| Program Version           | Version 7.0                       |
| Analysis Option           | Stratified SRS with FPC           |

**Estimates**

|                                      |                |
|--------------------------------------|----------------|
| Unweighted Retailer Violation Rate   | 11.9%          |
| Weighted Retailer Violation Rate     | 11.9%          |
| Standard Error                       | 0.9%           |
| Is SAMHSA Precision Requirement met? | YES            |
| Right-sided 95% Confidence Interval  | [0.0%, 13.4%]  |
| Two-sided 95% Confidence Interval    | [10.2%, 13.7%] |
| Design Effect                        | 1.0            |
| Accuracy Rate (unweighted)           | 97.3%          |
| Accuracy Rate (weighted)             | 97.3%          |
| Completion Rate (unweighted)         | 79.8%          |

**Sample Size for Current Year**

|                              |       |
|------------------------------|-------|
| Effective Sample Size        | 335   |
| Target (Minimum) Sample Size | 335   |
| Original Sample Size         | 335   |
| Eligible Sample Size         | 326   |
| Final Sample Size            | 260   |
| Overall Sampling Rate        | 80.3% |

SSES Table 2 (Synar Survey Results by Stratum and by OTC/VM)

STATE: GU

FFY: 2022

| Samp. Stratum                   | Var. Stratum | Outlet Frame Size | Estimated Outlet Population Size | Number of PSU Clusters Created | Number of PSU Clusters in Sample | Outlet Sample Size | Number of Eligible Outlets in Sample | Number of Sample Outlets Inspected | Number of Sample Outlets in Violation | Retailer Violation Rate(%) | Standard Error(%) |
|---------------------------------|--------------|-------------------|----------------------------------|--------------------------------|----------------------------------|--------------------|--------------------------------------|------------------------------------|---------------------------------------|----------------------------|-------------------|
| <b>All Outlets</b>              |              |                   |                                  |                                |                                  |                    |                                      |                                    |                                       |                            |                   |
| 1                               | 1            | 335               | 326                              | N/A                            | N/A                              | 335                | 326                                  | 260                                | 31                                    | 11.9%                      |                   |
| Total                           |              | 335               | 326                              |                                |                                  | 335                | 326                                  | 260                                | 31                                    | 11.9%                      | 0.9%              |
| <b>Over the Counter Outlets</b> |              |                   |                                  |                                |                                  |                    |                                      |                                    |                                       |                            |                   |
| 1                               | 1            | 334               | 326                              | N/A                            | N/A                              | 335                | 326                                  | 260                                | 31                                    | 11.9%                      |                   |
| Total                           |              | 334               | 326                              |                                |                                  | 335                | 326                                  | 260                                | 31                                    | 11.9%                      | 0.9%              |
| <b>Vending Machines</b>         |              |                   |                                  |                                |                                  |                    |                                      |                                    |                                       |                            |                   |
| 1                               | 1            | 1                 | 0                                | N/A                            | N/A                              | 0                  | 0                                    | 0                                  | 0                                     | 0.0%                       |                   |
| Total                           |              | 1                 | 0                                |                                |                                  | 0                  | 0                                    | 0                                  | 0                                     | 0.0%                       | 0.0%              |

**SSES Table 3 (Synar Survey Sample Tally Summary)**

STATE: GU

FFY: 2022

| Disposition Code                     | Description                                            | Count | Subtotal   |
|--------------------------------------|--------------------------------------------------------|-------|------------|
| EC                                   | Eligible and inspection complete outlet                | 260   |            |
| <b>Total (Eligible Completes)</b>    |                                                        |       | <b>260</b> |
| N1                                   | In operation but closed at time of visit               | 18    |            |
| N2                                   | Unsafe to access                                       | 0     |            |
| N3                                   | Presence of police                                     | 0     |            |
| N4                                   | Youth inspector knows salesperson                      | 0     |            |
| N5                                   | Moved to new location but not inspected                | 0     |            |
| N6                                   | Drive thru only/youth inspector has no drivers license | 0     |            |
| N7                                   | Tobacco out of stock                                   | 2     |            |
| N8                                   | Run out of time                                        | 0     |            |
| N9                                   | Other noncompletion (see below)                        | 46    |            |
| <b>Total (Eligible Noncompletes)</b> |                                                        |       | <b>66</b>  |
| I1                                   | Out of Business                                        | 0     |            |
| I2                                   | Does not sell tobacco products                         | 3     |            |
| I3                                   | Inaccessible by youth                                  | 0     |            |
| I4                                   | Private club or private residence                      | 0     |            |
| I5                                   | Temporary closure                                      | 5     |            |
| I6                                   | Can't be located                                       | 1     |            |
| I7                                   | Wholesale only/Carton sale only                        | 0     |            |
| I8                                   | Vending machine broken                                 | 0     |            |
| I9                                   | Duplicate                                              | 0     |            |
| I10                                  | Other ineligibility                                    | 0     |            |
| <b>Total (Ineligibles)</b>           |                                                        |       | <b>9</b>   |
| <b>Grand Total</b>                   |                                                        |       | <b>335</b> |

**Give reasons and counts for other noncompletion:**

| Reason                                                                                                                                          | Count |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| 290-335 Due to COVID-19 Pandemic increase in positive cases we felt it unsafe to conduct Synar inspections with the youth/underaged inspectors. | 46    |
|                                                                                                                                                 |       |
|                                                                                                                                                 |       |
|                                                                                                                                                 |       |
|                                                                                                                                                 |       |

**SSES Table 4 (Synar Survey Inspection Results by Youth Inspector Characteristics)**

STATE: GU

FFY: 2022

**Frequency Distribution**

| Gender      | Age      | Number of Inspectors | Attempted Buys | Successful Buys |
|-------------|----------|----------------------|----------------|-----------------|
| Male        | 14       | 0                    | 0              | 0               |
|             | 15       | 1                    | 9              | 0               |
|             | 16       | 2                    | 22             | 3               |
|             | 17       | 1                    | 13             | 0               |
|             | 18       | 0                    | 0              | 0               |
|             | 19       | 0                    | 0              | 0               |
|             | 20       | 0                    | 0              | 0               |
|             | Subtotal | 4                    | 44             | 3               |
| Female      | 14       | 0                    | 0              | 0               |
|             | 15       | 0                    | 0              | 0               |
|             | 16       | 5                    | 55             | 11              |
|             | 17       | 3                    | 82             | 4               |
|             | 18       | 0                    | 0              | 0               |
|             | 19       | 2                    | 40             | 6               |
|             | 20       | 2                    | 39             | 7               |
|             | Subtotal | 12                   | 216            | 28              |
| Other       |          | 0                    | 0              | 0               |
| Grand Total |          | 16                   | 260            | 31              |

**Buy Rate in Percent by Age and Gender**

| Age   | Male  | Female | Total |
|-------|-------|--------|-------|
| 14    | 0.0%  | 0.0%   | 0.0%  |
| 15    | 0.0%  | 0.0%   | 0.0%  |
| 16    | 13.6% | 20.0%  | 18.2% |
| 17    | 0.0%  | 4.9%   | 4.2%  |
| 18    | 0.0%  | 0.0%   | 0.0%  |
| 19    | 0.0%  | 15.0%  | 15.0% |
| 20    | 0.0%  | 17.9%  | 17.9% |
| Other |       |        | 0.0%  |
| Total | 6.8%  | 13.0%  | 11.9% |

| Outlet ID | Sampling Stratum | Population Size in Sampling Stratum | Population Variance Stratum | Population Size in Variance Stratum | Response Disposition Code | Violation Flag | Outlet Type | Youth Inspector ID | Youth Inspector Gender | Youth Inspector Age | VM Frame Size in Sampling Stratum | Type of Product (Cigarettes (1), Small Cigars/Cigarillos (2), Smokeless Tobacco (3), ENDS (4), Other (5)) | Retail Outlet Type (Gas Station (1), Tobacco Store (2), Restaurant (3), Hotel (4), Grocery (5), Drug store (6), Other (7)) | Clerk asked Youth Inspector for ID (Y=yes, N=no) |
|-----------|------------------|-------------------------------------|-----------------------------|-------------------------------------|---------------------------|----------------|-------------|--------------------|------------------------|---------------------|-----------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| 1         | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 2         | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 3         | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 4         | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 5         | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 6         | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 7         | 1                | 335                                 | 1                           | 335                                 | EC                        | 1              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | N                                                |
| 8         | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 9         | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 10        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 11        | 1                | 335                                 | 1                           | 335                                 | EC                        | 1              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | N                                                |
| 12        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 13        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 14        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 15        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 16        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 17        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 18        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 19        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 20        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 21        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 22        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | M                      | 16                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 23        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 24        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 25        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2132               | M                      | 16                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 26        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2131               | F                      | 17                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 27        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | N                                                |
| 28        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2128               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 29        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 30        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 31        | 1                | 335                                 | 1                           | 335                                 | N1                        |                | OTC         | 2129               | F                      | 17                  | 1                                 |                                                                                                           | 5                                                                                                                          | Y                                                |
| 32        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 33        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 34        | 1                | 335                                 | 1                           | 335                                 | N7                        |                | OTC         | 2129               | F                      | 17                  | 1                                 |                                                                                                           | 7                                                                                                                          | Y                                                |
| 35        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2128               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 36        | 1                | 335                                 | 1                           | 335                                 | EC                        | 1              | OTC         | 2128               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | N                                                |
| 37        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | N                                                |
| 38        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 39        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |
| 40        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 41        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 1                                                                                                                          | Y                                                |
| 42        | 1                | 335                                 | 1                           | 335                                 | EC                        | 0              | OTC         | 2129               | F                      | 17                  | 1                                 | 1                                                                                                         | 5                                                                                                                          | Y                                                |

|    |   |     |   |     |    |   |     |      |   |    |   |     |   |   |   |
|----|---|-----|---|-----|----|---|-----|------|---|----|---|-----|---|---|---|
| 43 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2129 | F | 17 | 1 | 1   | 1 | 5 | Y |
| 44 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2128 | F | 17 | 1 | 13  | 1 | 5 | N |
| 45 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2128 | F | 17 | 1 | 1   | 1 | 3 | Y |
| 46 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2129 | F | 17 | 1 | 1   | 1 | 1 | Y |
| 47 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2129 | F | 17 | 1 | 13  | 1 | 5 | N |
| 48 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2128 | F | 17 | 1 | 1   | 1 | 1 | Y |
| 49 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2128 | F | 17 | 1 | 1,3 | 1 | 5 | Y |
| 50 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2128 | F | 17 | 1 | 1   | 1 | 7 | Y |
| 51 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2129 | F | 17 | 1 | 1   | 1 | 5 | Y |
| 52 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2128 | F | 17 | 1 | 1   | 1 | 5 | Y |
| 53 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2128 | F | 17 | 1 | 1   | 1 | 5 | Y |
| 54 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2128 | F | 17 | 1 | 1   | 1 | 5 | N |
| 55 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2128 | F | 17 | 1 | 1   | 1 | 5 | Y |
| 56 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2128 | F | 17 | 1 | 1   | 1 | 5 | Y |
| 57 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 7 | N |
| 58 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | Y |
| 59 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | N |
| 60 | 1 | 335 | 1 | 335 | N1 | 0 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 7 | Y |
| 61 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | Y |
| 62 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 5 | Y |
| 63 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | Y |
| 64 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | Y |
| 65 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2125 | F | 19 | 1 | 1   | 1 | 5 | N |
| 66 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 5 | Y |
| 67 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 5 | Y |
| 68 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | Y |
| 69 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2125 | F | 19 | 1 | 1   | 1 | 1 | Y |
| 70 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 5 | Y |
| 71 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 1 | Y |
| 72 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2125 | F | 19 | 1 | 1   | 1 | 1 | Y |
| 73 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 7 | Y |
| 74 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2125 | F | 19 | 1 | 1   | 1 | 5 | Y |
| 75 | 1 | 335 | 1 | 335 | I2 | 1 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | N |
| 76 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2125 | F | 19 | 1 | 1   | 1 | 5 | Y |
| 77 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 1 | Y |
| 78 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | Y |
| 79 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2123 | F | 20 | 1 | 1   | 1 | 5 | N |
| 80 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2125 | F | 19 | 1 | 1   | 1 | 5 | Y |
| 81 | 1 | 335 | 1 | 335 | N1 | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | Y |
| 82 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2124 | M | 15 | 1 | 1   | 1 | 5 | Y |
| 83 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1   | 1 | 1 | Y |
| 84 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1   | 1 | 5 | N |
| 85 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2116 | F | 19 | 1 | 1   | 1 | 5 | Y |
| 86 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2120 | F | 16 | 1 | 1   | 1 | 5 | Y |
| 87 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1   | 1 | 5 | Y |
| 88 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1   | 1 | 5 | Y |
| 89 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1   | 1 | 5 | Y |
| 90 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1   | 1 | 5 | Y |
| 91 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1   | 1 | 5 | Y |
| 92 | 1 | 335 | 1 | 335 | N1 | 0 | OTC | 2120 | F | 16 | 1 | 1   | 1 | 7 | Y |
| 93 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1   | 1 | 5 | Y |

|     |   |     |   |     |    |   |     |      |   |    |   |   |   |
|-----|---|-----|---|-----|----|---|-----|------|---|----|---|---|---|
| 94  | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1 | Y |
| 95  | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1 | Y |
| 96  | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1 | Y |
| 97  | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1 | Y |
| 98  | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1 | Y |
| 99  | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1 | Y |
| 100 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1 | Y |
| 101 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1 | Y |
| 102 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1 | Y |
| 103 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 1220 | F | 16 | 1 | 1 | Y |
| 104 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1 | Y |
| 105 | 1 | 335 | 1 | 335 | N1 | 0 | OTC | 2120 | F | 16 | 1 | 1 | Y |
| 106 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1 | Y |
| 107 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 | 1 | Y |
| 108 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2116 | F | 19 | 1 | 1 | Y |
| 109 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2120 | F | 16 | 1 | 1 | Y |
| 110 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 111 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 112 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 113 | 1 | 335 | 1 | 335 | N1 | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 114 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 115 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 116 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 117 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 118 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 119 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 120 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2112 | F | 20 | 1 | 1 | N |
| 121 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 122 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 123 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 124 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 20 | 1 | 1 | Y |
| 125 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 126 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 20 | 1 | 1 | Y |
| 127 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 128 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 129 | 1 | 335 | 1 | 335 | N1 | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 130 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2112 | F | 20 | 1 | 1 | N |
| 131 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 132 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 133 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2113 | F | 16 | 1 | 1 | N |
| 134 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 135 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2113 | F | 16 | 1 | 1 | N |
| 136 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 | 1 | Y |
| 137 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 138 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 139 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | Y |
| 140 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 141 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | Y |
| 142 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |
| 143 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | Y |
| 144 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | Y |

|     |   |     |   |     |    |   |     |      |   |    |   |   |         |   |   |
|-----|---|-----|---|-----|----|---|-----|------|---|----|---|---|---------|---|---|
| 145 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 5 | Y |
| 146 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | 1       | 5 | Y |
| 147 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 5 | Y |
| 148 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | 1       | 1 | Y |
| 149 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 5 | Y |
| 150 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 1 | Y |
| 151 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | 1       | 5 | Y |
| 152 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | 1       | 1 | Y |
| 153 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 5 | Y |
| 154 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | 1       | 5 | Y |
| 155 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 5 | Y |
| 156 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 1 | Y |
| 157 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2113 | F | 16 | 1 | 1 | 1       | 1 | Y |
| 158 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 1 | Y |
| 159 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2117 | M | 17 | 1 | 1 | 1       | 1 | Y |
| 160 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2113 | F | 16 | 1 | 1 | 1       | 1 | N |
| 161 | 1 | 335 | 1 | 335 | N1 |   | OTC | 2120 | F | 16 |   |   |         |   | Y |
| 162 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 |   |   | 1,3     |   | Y |
| 163 | 1 | 335 | 1 | 335 | N1 |   | OTC | 2112 | F | 20 | 1 |   |         |   | N |
| 164 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2120 | F | 16 | 1 |   | 1       |   | N |
| 165 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2110 | F | 16 | 1 |   | 1       |   | N |
| 166 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 167 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 168 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1       |   | Y |
| 169 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 170 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2120 | F | 16 | 1 |   | 1,3     |   | N |
| 171 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1,3     |   | Y |
| 172 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 173 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2121 | F | 16 | 1 |   | 1,3,4   |   | Y |
| 174 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 175 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1,3,4   |   | Y |
| 176 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1       |   | Y |
| 177 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2112 | F | 16 | 1 |   | 1       |   | N |
| 178 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 179 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 180 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1       |   | Y |
| 181 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 182 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1       |   | Y |
| 183 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 184 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1       |   | Y |
| 185 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 186 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1,2,3,4 |   | Y |
| 187 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2120 | F | 16 | 1 |   | 1,2,3,4 |   | Y |
| 188 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 189 | 1 | 335 | 1 | 335 | I2 |   | OTC | 2120 | F | 16 | 1 |   |         |   | Y |
| 190 | 1 | 335 | 1 | 335 | I2 |   | OTC | 2112 | F | 20 | 1 |   |         |   | Y |
| 191 | 1 | 335 | 1 | 335 | I5 |   | OTC | 2112 | F | 20 | 1 |   |         |   | Y |
| 192 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2120 | F | 16 | 1 |   | 1       |   | N |
| 193 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 194 | 1 | 335 | 1 | 335 | EC | 0 | OTC | 2112 | F | 20 | 1 |   | 1       |   | Y |
| 195 | 1 | 335 | 1 | 335 | EC | 1 | OTC | 2120 | F | 16 | 1 |   | 1       |   | N |



|     |   |     |   |     |     |      |   |    |   |     |     |   |   |
|-----|---|-----|---|-----|-----|------|---|----|---|-----|-----|---|---|
| 247 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1   | 1   | 5 | Y |
| 248 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1   | 1   | 5 | Y |
| 249 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 250 | 1 | 335 | 1 | 335 | OTC | 2128 | F | 17 | 1 | 1,3 | 1,3 | 5 | N |
| 251 | 1 | 335 | 1 | 335 | OTC | 2128 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 252 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 253 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1   | 1   | 5 | Y |
| 254 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 255 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 256 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 257 | 1 | 335 | 1 | 335 | OTC | 2128 | F | 17 | 1 | 1,3 | 1,3 | 1 | Y |
| 258 | 1 | 335 | 1 | 335 | OTC | 2128 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 259 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 260 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 261 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 262 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 263 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 264 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 265 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 266 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 267 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 268 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 269 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 270 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 1 | Y |
| 271 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 272 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 273 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 1 | Y |
| 274 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 7 | Y |
| 275 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 276 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 277 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 278 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 279 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 280 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 281 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 282 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 283 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 284 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 285 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 286 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 287 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 288 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 289 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 290 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 291 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 292 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 293 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 294 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 295 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 296 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |
| 297 | 1 | 335 | 1 | 335 | OTC | 2129 | F | 17 | 1 | 1,3 | 1,3 | 5 | Y |

|     |   |     |   |     |    |     |    |    |   |   |
|-----|---|-----|---|-----|----|-----|----|----|---|---|
| 298 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 299 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 300 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 301 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 5 |
| 302 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 5 |
| 303 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 304 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 305 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 306 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 307 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 308 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 309 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 310 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 311 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 312 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 313 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 314 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 315 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 316 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 317 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 318 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 319 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 320 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 321 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 322 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 323 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 324 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 325 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 3 |
| 326 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 327 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 328 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 329 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 330 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 331 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 332 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 333 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 334 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |
| 335 | 1 | 335 | 1 | 335 | N9 | OTC | 99 | 99 | 1 | 7 |

SSSES Table 6 (Synar Survey Inspection Results by Type of Product)

STATE: GU  
FFY: 2022

| Frequency Distribution and Buy Rate |                |                 |                    |
|-------------------------------------|----------------|-----------------|--------------------|
| Product Type                        | Attempted Buys | Successful Buys | Violation Rate (%) |
| Cigarettes                          | 209            | 26              | 12.4%              |
| Small cigars/Cigarillos             | 0              | 0               | 0.0%               |
| Smokeless tobacco                   | 0              | 0               | 0.0%               |
| ENDS                                | 0              | 0               | 0.0%               |
| Other                               | 0              | 0               | 0.0%               |
| Missing                             | 0              | 0               | 0.0%               |
| Invalid                             | 51             | 5               | 9.8%               |
| Grand Total                         | 260            | 31              | 11.9%              |

SSSES Table 6 (Synar Survey Inspection Results by Type of Product)

STATE: GU  
FFY: 2022

Buy Rate by Type of Product, Age, and Gender

| Male                    |      |      |       |      |      |      |      |       |
|-------------------------|------|------|-------|------|------|------|------|-------|
| Product Type            | Age  |      |       |      |      |      |      | Total |
|                         | 14   | 15   | 16    | 17   | 18   | 19   | 20   |       |
| Cigarettes              | 0.0% | 0.0% | 12.5% | 0.0% | 0.0% | 0.0% | 0.0% | 5.3%  |
| Small cigars/Cigarillos | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |
| Smokeless tobacco       | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |
| ENDS                    | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |
| Other                   | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |
| Missing                 | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |
| Invalid                 | 0.0% | 0.0% | 16.7% | 0.0% | 0.0% | 0.0% | 0.0% | 16.7% |
| Total Male              | 0.0% | 0.0% | 13.6% | 0.0% | 0.0% | 0.0% | 0.0% | 6.8%  |

| Female                  |      |      |       |      |      |       |       |       |
|-------------------------|------|------|-------|------|------|-------|-------|-------|
| Product Type            | Age  |      |       |      |      |       |       | Total |
|                         | 14   | 15   | 16    | 17   | 18   | 19    | 20    |       |
| Cigarettes              | 0.0% | 0.0% | 20.8% | 3.8% | 0.0% | 16.7% | 17.6% | 14.0% |
| Small cigars/Cigarillos | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Smokeless tobacco       | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| ENDS                    | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Other                   | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Missing                 | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Invalid                 | 0.0% | 0.0% | 14.3% | 6.9% | 0.0% | 0.0%  | 20.0% | 8.9%  |
| Total Female            | 0.0% | 0.0% | 20.0% | 4.9% | 0.0% | 15.0% | 17.9% | 13.0% |

| All                     |      |      |       |      |      |       |       |       |
|-------------------------|------|------|-------|------|------|-------|-------|-------|
| Product Type            | Age  |      |       |      |      |       |       | Total |
|                         | 14   | 15   | 16    | 17   | 18   | 19    | 20    |       |
| Cigarettes              | 0.0% | 0.0% | 18.8% | 3.0% | 0.0% | 16.7% | 17.6% | 12.4% |
| Small cigars/Cigarillos | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Smokeless tobacco       | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| ENDS                    | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Other                   | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Missing                 | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Invalid                 | 0.0% | 0.0% | 15.4% | 6.9% | 0.0% | 0.0%  | 20.0% | 9.8%  |
| Grand Total             | 0.0% | 0.0% | 18.2% | 4.2% | 0.0% | 15.0% | 17.9% | 11.9% |

SSSES Table 7 (Synar Survey Inspection Results by Type of Retail Outlet)

STATE: GU  
FFY: 2022

| Frequency Distribution and Buy Rate |                |                 |                    |
|-------------------------------------|----------------|-----------------|--------------------|
| Retail Outlet                       | Attempted Buys | Successful Buys | Violation Rate (%) |
| Gas Station                         | 40             | 1               | 2.5%               |
| Tobacco Store                       | 0              | 0               | 0.0%               |
| Restaurant                          | 1              | 0               | 0.0%               |
| Hotel                               | 0              | 0               | 0.0%               |
| Grocery Store                       | 180            | 26              | 14.4%              |
| Drug Store                          | 0              | 0               | 0.0%               |
| Other                               | 39             | 4               | 10.3%              |
| Missing                             | 0              | 0               | 0.0%               |
| Invalid                             | 0              | 0               | 0.0%               |
| Grand Total                         | 260            | 31              | 11.9%              |

SSSES Table 7 (Synar Survey Inspection Results by Type of Retail Outlet)

STATE: GU  
FFY: 2022

| Buy Rate by Type of Retail Outlet, Age, and Gender |      |      |       |      |      |      |      |       |  |
|----------------------------------------------------|------|------|-------|------|------|------|------|-------|--|
| Male                                               |      |      |       |      |      |      |      |       |  |
| Retail Outlet                                      | Age  |      |       |      |      |      |      | Total |  |
|                                                    | 14   | 15   | 16    | 17   | 18   | 19   | 20   |       |  |
| Gas Station                                        | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |  |
| Tobacco Store                                      | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |  |
| Restaurant                                         | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |  |
| Hotel                                              | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |  |
| Grocery Store                                      | 0.0% | 0.0% | 16.7% | 0.0% | 0.0% | 0.0% | 0.0% | 8.8%  |  |
| Drug Store                                         | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |  |
| Other                                              | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |  |
| Missing                                            | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |  |
| Invalid                                            | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%  |  |
| Total Male                                         | 0.0% | 0.0% | 13.6% | 0.0% | 0.0% | 0.0% | 0.0% | 6.8%  |  |

| Female        |      |      |       |      |      |       |       |       |       |
|---------------|------|------|-------|------|------|-------|-------|-------|-------|
| Retail Outlet | Age  |      |       |      |      |       |       |       | Total |
|               | 14   | 15   | 16    | 17   | 18   | 19    | 20    |       |       |
| Gas Station   | 0.0% | 0.0% | 8.3%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 3.0%  |       |
| Tobacco Store | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |       |
| Restaurant    | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |       |
| Hotel         | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |       |
| Grocery Store | 0.0% | 0.0% | 21.2% | 7.5% | 0.0% | 16.7% | 23.3% | 15.8% |       |
| Drug Store    | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |       |
| Other         | 0.0% | 0.0% | 30.0% | 0.0% | 0.0% | 20.0% | 0.0%  | 11.1% |       |
| Missing       | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |       |
| Invalid       | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |       |
| Total Female  | 0.0% | 0.0% | 20.0% | 4.9% | 0.0% | 15.0% | 17.9% | 13.0% |       |

| All           |      |      |       |      |      |       |       |       |  |
|---------------|------|------|-------|------|------|-------|-------|-------|--|
| Retail Outlet | Age  |      |       |      |      |       |       | Total |  |
|               | 14   | 15   | 16    | 17   | 18   | 19    | 20    |       |  |
| Gas Station   | 0.0% | 0.0% | 6.7%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 2.5%  |  |
| Tobacco Store | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |  |
| Restaurant    | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |  |
| Hotel         | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |  |
| Grocery Store | 0.0% | 0.0% | 19.6% | 6.6% | 0.0% | 16.7% | 23.3% | 14.4% |  |
| Drug Store    | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |  |
| Other         | 0.0% | 0.0% | 27.3% | 0.0% | 0.0% | 20.0% | 0.0%  | 10.3% |  |
| Missing       | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |  |
| Invalid       | 0.0% | 0.0% | 0.0%  | 0.0% | 0.0% | 0.0%  | 0.0%  | 0.0%  |  |
| Grand Total   | 0.0% | 0.0% | 18.2% | 4.2% | 0.0% | 15.0% | 17.9% | 11.9% |  |

SSES Table 8 (Synar Survey Inspection Results by Clerk Asked for ID)

STATE: GU  
FFY: 2022

| Frequency Distribution and Buy Rate |                |                 |                    |
|-------------------------------------|----------------|-----------------|--------------------|
| Clerk Asked for ID                  | Attempted Buys | Successful Buys | Violation Rate (%) |
| Yes                                 | 225            | 4               | 1.8%               |
| No                                  | 33             | 27              | 81.8%              |
| Missing                             | 1              | 0               | 0.0%               |
| Invalid                             | 1              | 0               | 0.0%               |
| Grand Total                         | 260            | 31              | 11.9%              |

SSES Table 8 (Synar Survey Inspection Results by Clerk Asked for ID)

STATE: GU  
FFY: 2022

Buy Rate by Clerk Asked for ID, Age, and Gender

| Male               |      |      |        |      |      |      |      |        |  |
|--------------------|------|------|--------|------|------|------|------|--------|--|
| Clerk Asked for ID | Age  |      |        |      |      |      |      | Total  |  |
|                    | 14   | 15   | 16     | 17   | 18   | 19   | 20   |        |  |
| Yes                | 0.0% | 0.0% | 0.0%   | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%   |  |
| No                 | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% |  |
| Missing            | 0.0% | 0.0% | 0.0%   | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%   |  |
| Invalid            | 0.0% | 0.0% | 0.0%   | 0.0% | 0.0% | 0.0% | 0.0% | 0.0%   |  |
| Total Male         | 0.0% | 0.0% | 13.6%  | 0.0% | 0.0% | 0.0% | 0.0% | 6.8%   |  |

| Female             |      |      |        |       |      |       |       |       |
|--------------------|------|------|--------|-------|------|-------|-------|-------|
| Clerk Asked for ID | Age  |      |        |       |      |       |       | Total |
|                    | 14   | 15   | 16     | 17    | 18   | 19    | 20    |       |
| Yes                | 0.0% | 0.0% | 2.3%   | 0.0%  | 0.0% | 2.9%  | 6.1%  | 2.2%  |
| No                 | 0.0% | 0.0% | 100.0% | 50.0% | 0.0% | 83.3% | 83.3% | 80.0% |
| Missing            | 0.0% | 0.0% | 0.0%   | 0.0%  | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Invalid            | 0.0% | 0.0% | 0.0%   | 0.0%  | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Total Female       | 0.0% | 0.0% | 20.0%  | 4.9%  | 0.0% | 15.0% | 17.9% | 13.0% |

| All                |      |      |        |       |      |       |       |       |
|--------------------|------|------|--------|-------|------|-------|-------|-------|
| Clerk Asked for ID | Age  |      |        |       |      |       |       | Total |
|                    | 14   | 15   | 16     | 17    | 18   | 19    | 20    |       |
| Yes                | 0.0% | 0.0% | 1.6%   | 0.0%  | 0.0% | 2.9%  | 6.1%  | 1.8%  |
| No                 | 0.0% | 0.0% | 100.0% | 50.0% | 0.0% | 83.3% | 83.3% | 81.8% |
| Missing            | 0.0% | 0.0% | 0.0%   | 0.0%  | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Invalid            | 0.0% | 0.0% | 0.0%   | 0.0%  | 0.0% | 0.0%  | 0.0%  | 0.0%  |
| Grand Total        | 0.0% | 0.0% | 18.2%  | 4.2%  | 0.0% | 15.0% | 17.9% | 11.9% |